Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
March 2014—Waters Corp. announced three UNIFI Scientific Information System solutions: Waters Glycan Application Solution with UNIFI, Forensic Toxicology Screening Application Solution with UNIFI, and Natural Products Application Solution with UNIFI. Each application features a proprietary, comprehensive library of relevant molecules.
March 2014—Agilent Technologies introduced the IQFISH FFPE Hybridization buffer, which enables one-hour hybridization for FISH processing on formalin-fixed paraffin-embedded tissue samples.
March 2014—Medical Chemical’s Total-Fix stool fixative for ova and parasites is now patented. Total-Fix does not contain any mercury, formaldehyde, or PVA. It is a multi-use, single-vial system that preserves stool specimens for staining (Trichrome/iron hematoxylin), concentration, Giardia and Cryptosporidium antigens, and fluorescent assays. Total-Fix also preserves molecular material in stool for molecular (real PCR) assays.
March 2014—Qiagen expanded its strategic partnership with Exosome Diagnostics to develop a noninvasive molecular in vitro diagnostic. The novel blood-based diagnostic detects certain mutations of an undisclosed gene associated with non-small cell lung cancer and other malignancies and has the potential to be paired with several new anticancer therapeutics.
March 2014—Beckman Coulter Diagnostics received FDA 510(k) clearance for its Access Total βhCG (5th IS) assay, the first βhCG assay standardized to the highly purified World Health Organization 5th International Standard (IS) for chorionic gonadotropin.
March 2014—The Tosoh G8 (Tosoh Automated Glycohemoglobin Analyzer HLC-723G8) has been cleared by the FDA as the first high-performance liquid chromatography (HPLC) instrument for use as an aid in diagnosing diabetes and identifying patients who may be at risk for developing diabetes. The Tosoh G8 was initially cleared in 2008 as a diabetes monitoring device; the intended use has now been expanded to screening as well.
March 2014—Affymetrix received FDA 510(k) clearance to market its CytoScan Dx assay, intended for the postnatal detection of DNA copy number variants in patients referred for chromosomal testing. CytoScan Dx is designed to help diagnose children’s developmental and intellectual disabilities more comprehensively by enabling a high-resolution, genome-wide analysis of genetic aberrations.
March 2014—Agilent Technologies introduced SureFISH ALK, ROS1, and RET break-apart translocation probes, expanding its offering of oligonucleotide-based fluorescent in situ hybridization products. The probes are repeat-free, able to target specific sequences of interest, and use high-fidelity oligos designed in silico.
March 2014—The Center for Phlebotomy Education will conduct intensive three-day seminars in Indianapolis and San Francisco for those who train or manage phlebotomists. The event will provide strategies to help attendees reduce expenses by cultivating satisfied, long-term employees; cut costs through process improvement; nurture professionalism and responsibility among specimen-collection personnel; implement different learning styles to maximize teaching; and mentor students and new staff.
March 2014—Enzo Life Sciences’ high-sensitivity Grp78/BiP ELISA kit is an endoplasmic reticulum-specific homologue of Hsp70, serving as a critical stress-sensing chaperone and regulator of the unfolded protein response (UPR). Grp78 helps fold misfolded proteins, prevent protein aggregation, and regulate protein degradation, synthesis, transportation, and oligomerization.
